Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Other hematologic neoplasm 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Temozolomide 19 Magnetic Resonance Spectroscopy 16 Radiosurgery 12 Bevacizumab 12 Radiotherapy 10 Radiation 8 pembrolizumab 6 Specimen Handling 6 Methotrexate 6 Surgical Procedures, Operative 5 Topotecan 4 TIC10 compound 4 Isotretinoin 4 Carmustine 4 Carboplatin 4 abemaciclib 3 Trastuzumab 3 Thiotepa 3 Standard of Care 3 Nivolumab 3 Magnetic Resonance Imaging 3 Lomustine 3 Irinotecan 3 Erlotinib Hydrochloride 3 Drug Therapy 3 Dexamethasone 3 vandetanib 2 thymoglobulin 2 temsirolimus 2 pazopanib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × ficlatuzumab × CNS × Clear all

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡